Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 12/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 12/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13833142 | 0.86 | PPARG (0.43) | HCRTR1HCRTR2HDAC1HDAC8HDAC6 | |
| SCHEMBL15604676 | 0.81 | HCRTR1 (0.61) | HCRTR1HCRTR2HDAC1HDAC8HDAC6 | |
| SCHEMBL15522013 | 0.80 | HCRTR1 (0.41) | HCRTR1HCRTR2PPARGPPARAHCAR2 | |
| SCHEMBL13833216 | 0.79 | ALDH1A1 (0.39) | HCRTR1HCRTR2HDAC1HDAC8HDAC6 | |
| SCHEMBL16812741 | 0.79 | HCRTR1 (0.52) | HCRTR1HCRTR2HDAC1HDAC8HDAC6 | |
| SCHEMBL15518985 | 0.76 | HCRTR1 (0.63) | HCRTR1HCRTR2 | |
| SCHEMBL15522028 | 0.76 | HCRTR2 (0.72) | HCRTR1HCRTR2 | |
| SCHEMBL15522011 | 0.75 | HCRTR1 (0.46) | HCRTR1HCRTR2PPARGPPARAHCAR2 | |
| SCHEMBL15521964 | 0.75 | HCRTR1 (0.62) | HCRTR1HCRTR2 | |
| SCHEMBL13833377 | 0.75 | HCRTR1 (0.73) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | HCRTR2, HCRTR1, HTT | HCRTR1 2/4885HCRTR2 1/4885HDAC1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.